Literature DB >> 18923919

Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria.

F Porta1, I Roato, A Mussa, M Repici, E Gorassini, M Spada, R Ferracini.   

Abstract

Phenylketonuria (PKU) is commonly complicated by a progressive bone impairment of uncertain aetiology. The therapeutic phenylalanine (Phe)-restricted diet and the possible noxious effects of high plasma Phe concentrations on bone have previously been suggested as possible determinant factors. Since osteoclasts are involved in bone reabsorption, they could play a role in determining bone damage in PKU. The reported increased excretion of bone resorption markers in PKU patients is consistent with this hypothesis. Although different diseases characterized by bone loss have been related to increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells (PBMCs), to date there is no evidence of increased osteoclast formation in PKU. In this study, we compared the spontaneous osteoclastogenesis from PBMCs in 20 patients affected by PKU with that observed in age- and sex-matched healthy subjects. Phenylketonuric patients showed the number of osteoclasts to be almost double that observed in controls (159.9 ± 79.5 and 87.8 ± 44.7, respectively; p = 0.001). Moreover, a strict direct correlation between the spontaneous osteoclastogenesis in PKU patients and the mean blood Phe concentrations in the preceding year was observed (r = 0.576; p = 0.010). An imbalance between bone formation and bone resorption might explain, at least in part, the pathogenesis of bone loss in this disease. These findings could provide new insights into the biological mechanisms underlying bone damage in PKU.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923919     DOI: 10.1007/s10545-008-0907-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis.

Authors:  Patrizia D'Amelio; Anastasia Grimaldi; Gian Piero Pescarmona; Cristina Tamone; Ilaria Roato; Giancarlo Isaia
Journal:  FASEB J       Date:  2004-12-20       Impact factor: 5.191

2.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

3.  Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?

Authors:  Pablo Millet; M Antonia Vilaseca; Carme Valls; Belén Pérez-Dueñas; Rafael Artuch; Lilian Gómez; Nilo Lambruschini; Jaume Campistol
Journal:  Clin Biochem       Date:  2005-10-27       Impact factor: 3.281

4.  Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography.

Authors:  B Schwahn; E Mokov; K Scheidhauer; B Lettgen; E Schönau
Journal:  Acta Paediatr       Date:  1998-01       Impact factor: 2.299

5.  Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr).

Authors:  E Cacciari; S Milani; A Balsamo; E Spada; G Bona; L Cavallo; F Cerutti; L Gargantini; N Greggio; G Tonini; A Cicognani
Journal:  J Endocrinol Invest       Date:  2006 Jul-Aug       Impact factor: 4.256

Review 6.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

7.  Bone mineral status in children with phenylketonuria under treatment.

Authors:  A Al-Qadreh; K H Schulpis; H Athanasopoulou; C Mengreli; A Skarpalezou; I Voskaki
Journal:  Acta Paediatr       Date:  1998-11       Impact factor: 2.299

8.  Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.

Authors:  Ping Li; Edward M Schwarz; Regis J O'Keefe; Lin Ma; R John Looney; Christopher T Ritchlin; Brendan F Boyce; Lianping Xing
Journal:  Arthritis Rheum       Date:  2004-01

9.  Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer.

Authors:  I Roato; E Gorassini; L Buffoni; P Lyberis; E Ruffini; L Bonello; I Baldi; L Ciuffreda; A Mussa; R Ferracini
Journal:  Lung Cancer       Date:  2007-12-03       Impact factor: 5.705

10.  Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study.

Authors:  Francesco Porta; Marco Spada; Roberto Lala; Alessandro Mussa
Journal:  Ultrasound Med Biol       Date:  2008-03-03       Impact factor: 2.998

View more
  9 in total

1.  Cross-talk between T cells and osteoclasts in bone resorption.

Authors:  Lucia D'Amico; Ilaria Roato
Journal:  Bonekey Rep       Date:  2012-06-06

Review 2.  Nutritional issues in treating phenylketonuria.

Authors:  François Feillet; Carlo Agostoni
Journal:  J Inherit Metab Dis       Date:  2010-02-12       Impact factor: 4.982

3.  A New View of Bone Loss in Phenylketonuria.

Authors:  Steven F Dobrowolski; Irina L Tourkova; Cayla R Sudano; Quitterie C Larrouture; Harry C Blair
Journal:  Organogenesis       Date:  2021-08-25       Impact factor: 2.316

4.  Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.

Authors:  Ilaria Roato; Francesco Porta; Alessandro Mussa; Lucia D'Amico; Ludovica Fiore; Davide Garelli; Marco Spada; Riccardo Ferracini
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  Generation of urine-derived induced pluripotent stem cells from a patient with phenylketonuria.

Authors:  Zijuan Qi; Yazhou Cui; Liang Shi; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-05

Review 6.  Bone health in phenylketonuria: a systematic review and meta-analysis.

Authors:  Serwet Demirdas; Katie E Coakley; Peter H Bisschop; Carla E M Hollak; Annet M Bosch; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

7.  Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU.

Authors:  Katherine E Durrer; Michael S Allen; Ione Hunt von Herbing
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

8.  A Low-Phenylalanine-Containing Whey Protein Hydrolysate Stimulates Osteogenic Activity through the Activation of p38/Runx2 Signaling in Osteoblast Cells.

Authors:  Tingting Bu; Yuting Ren; Songfeng Yu; Jiexia Zheng; Ling Liu; Peilong Sun; Jianping Wu; Kai Yang
Journal:  Nutrients       Date:  2022-07-29       Impact factor: 6.706

9.  Bone Status in Patients with Phenylketonuria: A Systematic Review.

Authors:  María José de Castro; Carmela de Lamas; Paula Sánchez-Pintos; Domingo González-Lamuño; María Luz Couce
Journal:  Nutrients       Date:  2020-07-20       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.